Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity (Q39772204)

14 September 2017

Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity (English)

1 reference

14 September 2017

0 references

Gulcan Saylam Kurtipek

1

1 reference

14 September 2017

Recep Kesli

2

1 reference

14 September 2017

Fatma Tuncez Akyurek

3

1 reference

14 September 2017

Fikret Akyurek

4

1 reference

14 September 2017

Arzu Ataseven

5

1 reference

14 September 2017

Yuksel Terzi

6

1 reference

14 September 2017

12 May 2016

1 reference

International Journal of Rheumatic Diseases

14 September 2017

1 reference

Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease.

14 September 2017

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Why high suPAR is not super--diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

The physiological structure of human C-reactive protein and its complex with phosphocholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn's disease from intestinal lymphoma, intestinal tuberculosis and Behcet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12873

21 January 2018

Identifiers

DOI

10.1111/1756-185X.12873

1 reference

14 September 2017

1 reference